Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial

IMPORTANCE: New therapeutic options for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) are needed. This study evaluated dual checkpoint combination therapy in patients with mPDAC. OBJECTIVE: To evaluate the safety and efficacy of the anti–PD-L1 (programmed death-ligand 1) antibody...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JAMA Oncol
Autori principali: O’Reilly, Eileen M., Oh, Do-Youn, Dhani, Neesha, Renouf, Daniel J., Lee, Myung Ah, Sun, Weijing, Fisher, George, Hezel, Aram, Chang, Shao-Chun, Vlahovic, Gordana, Takahashi, Osamu, Yang, Yin, Fitts, David, Philip, Philip Agop
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Medical Association 2019
Soggetti:
Original Investigation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6647002/
https://ncbi.nlm.nih.gov/pubmed/31318392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1588
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi